Future research priorities should focus on longitudinal validation studies to establish NSE's predictive value for neuropathy development and progression, technology development for point-of-care testing to enhance global accessibility and clinical utility, investigation of NSE in combination with other biomarkers to enhance diagnostic accuracy and provide mechanistic insights, clinical trials investigating whether NSE-guided treatment strategies improve outcomes compared to standard care, and validation in different ethnic populations to establish global applicability. Here, ENO2 is linked to neuropathy.